

Realizing the Clinical Potential of Computational Psychiatry: Report from the Banbury Center Meeting, February 2019

Michael Browning^{a*}, Cameron S. Carter^b, Christopher Chatham^c, Hanneke Den Ouden^d, Claire M Gillan^e, Justin T. Baker^f, Adam M. Chekroud^g, Roshan Cools^h, Peter Dayanⁱ, James Gold^j, Rita Z. Goldstein^k, Catherine A. Hartley^l, Adam Kepecs^m, Rebecca P. Lawsonⁿ, Janaina Mourao-Miranda^o, Mary L. Phillips^p, Diego A. Pizzagalli^q, Albert Powers^r, David Rindskopf^s, Jonathan P Roiser^t, Katharina Schmack^u, Daniela Schiller^v, Miriam Sebold^w, Klaas Enno Stephan^x, Michael J Frank^{y+}, Quentin Huys^{z+}, Martin Paulus^{zz+}

*Corresponding author

+Meeting co-organizers; alphabetical order

^a Department of Psychiatry, University of Oxford, Oxford, UK & Oxford Health NHS Trust: michael.browning@psych.ox.ac.uk

^b Departments of Psychiatry and Psychology, University of California at Davis

^c Neuroscience & Rare Diseases (NRD), Roche Pharma Research & Early Development, Roche Innovation Center Basel

^d Radboud University, Donders Institute for Brain, Cognition and Behaviour.

^e School of Psychology, Trinity College Dublin, Dublin, Ireland

^f Institute for Technology in Psychiatry, McLean Hospital and Department of Psychiatry, Harvard Medical School

^g Spring Health, New York City

^h Radboud University Medical Center, Department of Psychiatry, Nijmegen, The Netherlands & Donders Institute for Cognition, Brain and Behaviour, Centre for Cognitive Neuroimaging

ⁱ Max Planck Institute for Biological Cybernetics, Tübingen, Germany

^j Maryland Psychiatric Research Center, University of Maryland School of Medicine

^k Dept. of Psychiatry & Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY

^l Department of Psychology, New York University

^m Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

ⁿ Department of Psychology, University of Cambridge, Cambridge, UK.

^o Centre for Medical Image Computing, Department of Computer Science and Max Planck Centre for Computational Psychiatry and Ageing Research, University College London, UK

^p Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA

^q Department of Psychiatry, Harvard Medical School & McLean Hospital, Belmont, MA

^r Department of Psychiatry, Yale University School of Medicine, New Haven, CT

^s Educational Psychology, CUNY Graduate Center, New York, NY

^t Institute of Cognitive Neuroscience, University College London, London, UK

^u Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

^v Dept. of Psychiatry & Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY

^w Charité – Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Germany

^xTranslational Neuromodeling Unit (TNU), Institute for Biomedical Engineering, University of Zurich & ETH Zurich, Switzerland; Wellcome Centre for Human Neuroimaging, University College London. 12 Queen Square, London, WC1N, 3AR, UK; Max Planck Institute for Metabolism Research, Gleueler Strasse 50, 50931 Cologne, Germany

^yCarney Institute for Brain Science, Dept of Cognitive, Linguistic & Psychological Sciences, Brown University, Providence, RI

^z Division of Psychiatry and Max-Planck-UCL Centre for Computational Psychiatry and Ageing Research, University College London, UK and Translational Neuromodeling Unit (TNU), Institute for Biomedical Engineering, University of Zurich & ETH Zurich, Switzerland

^{zz}Laureate Institute for Brain Research, Tulsa, OK

Keywords: Computational Psychiatry, Reliability, Validity, Collaboration

Word count: 1939

Number Figures: 1

Number Tables: 1

Computational psychiatry is an emerging field that examines phenomena in mental illness using formal techniques from computational neuroscience, mathematical psychology and machine learning (1–6). These techniques can be used in a theory-driven manner to gain algorithmic insight into neural or cognitive processes and in a data-driven way to identify predictive and explanatory relationships in complex datasets. The approaches complement each other: theory-driven models can be used to infer mechanisms, and the resulting measurements can be used in data-driven approaches for prediction. Data-driven algorithms can be used to answer theory-driven questions and pose quantitative problems requiring theoretical analysis. Recent computational studies have successfully described and measured novel mechanisms in a range of disorders (7–11), and have identified novel predictors of treatment response (12, 13). These methods hold the potential to improve identification of relevant clinical variables, and could be superior to classification based on traditional behavioral or neural data alone (14–17). However, these promising results have been slow to influence clinical practice or to improve patient outcomes.

In February 2019 a workshop was convened at the Banbury Centre at Cold Spring Harbor, NY. The purpose of the meeting was to identify key developments required in the practice and infrastructure of computational psychiatry research to accelerate its ability to address real world clinical problems in the near future. This report provides a summary of the conclusions of the meeting. At its core are suggestions to improve the measurement properties of computational assays through a rapid, iterative process that leverages coordinated waves of online and clinical testing, followed by deployment of the assays in innovative study designs to address clinically relevant questions. We particularly focus on theory-driven tasks but, where possible, the potential of data-driven approaches is also highlighted. Finally, the report suggests that for the promise of computational psychiatry to be realized, the research environment must be developed to encourage large-scale, collaborative, interdisciplinary consortia.

We first summarize the need for computational assays with improved measurement properties and describe an iterative optimization and validation procedure by which such assays may be developed and deployed in clinically informative studies. We then consider broader adaptations to the research environment that may accelerate the translation of these techniques.

Computational assays for clinical applications – what is missing from current research practice?

Measurement

A key application of computational assays is the estimation of latent behavioral and cognitive variables that underlie clinical observations and measurements. Theory-driven approaches rely extensively on generative models i.e., formal descriptions of the underlying neural and mental processes that are believed to generate empirical observations (see 18 for an example). Fitting generative models to observations has a number of potential advantages. First, it may allow identification and measurement of processes not easily captured by traditional analysis (19), second generative models may improve the validity and reliability by which a process is measured. For instance, generative models can describe, and hence be informed by, latent constructs that tie different features (e.g. reaction time and choice) and modalities (e.g. behavior and physiology) together in a holistic manner (20–23). They also allow artificial data to be simulated and therefore a degree of measurement optimization to occur *in silico* before the assay is deployed in practice (see Table 1 for details). However, these features do not by themselves guarantee that computational assays provide reliable and valid measures of underlying processes. Rather, the measurement properties of an assay must be assessed and iteratively optimized (see Table 1 for a summary of computation-specific and general metrics of

reliability and validity). Though there are notable exceptions (24–27) the issue of measurement in computational psychiatry has not yet attracted due attention. A principled and efficient process of assay development that optimizes measurement properties from the outset is a key outcome of the proposed framework described below.

Deployment

Beyond questions of measurement, a second crucial factor in translating computational assays to clinical application is the deployment of the assays in studies that are able to address clinically useful questions. While cross-sectional designs can be used to assess associations between symptoms and computational processes, they provide relatively limited information on the clinical utility of an assay. Alternative study designs which test the degree to which an assay provides predictive information useful to clinical decision-making, or the causal relationships between computationally measured processes and symptoms are likely to be particularly important here. Data-driven techniques are particularly well suited to deployment in predictive studies.

Developmental pipeline for clinically useful computational assays

Here we outline a potential, and necessarily collaborative, framework by which promising computational assays, arising from prior clinical, pre-clinical or theoretical work, may be efficiently developed, validated and deployed to address clinically interesting questions (Figure 1).

Establishing and optimizing the measurement characteristics of novel assays

Step 1: Assay optimization

First, the important measurement factors of the assay required to address a specific clinical question are selected and then the structure of the assay is altered to optimize these. Table 1 outlines a non-exhaustive list of important metrics. The selected factors may include both specific computational properties such as parameter identifiability (see Table 1) as well as practical features of an assay (e.g. duration to complete, complexity etc) and clinical validity (e.g. correlation with symptoms or treatment response). An objective function, constructed to reflect the specific priorities of a research project including factors to maximize (e.g. sensitivity to manipulations of key task variables, compliance, parameter identifiability) and minimize (e.g. task duration) may then be formalized in which several factors are combined to produce a single metric of measurement performance. The assay may then be optimized by iterative testing either in silico (Table 1), using high-throughput online data collection (28) or if necessary in more deeply phenotyped clinical populations. Here, optimization occurs by systematically varying aspects of the assay's configuration (e.g., number of trials per condition, timing of stimulus presentation, reward incentives) in order to maximize the objective function. In some cases, this may also include hand-designed qualitative changes (e.g. to improve the task instructions used). Optimization of data-driven approaches may follow a similar trajectory with, for example, the data features being passed to a classifier that is optimized in terms of the predictive validity of the classifier or the practicality of collecting the data.

Step 2: Latent structure validation

Although individual model parameters may underlie specific neurocognitive processes, key constructs of clinical relevance are likely to consist of a latent structure of relations between multiple such parameters within or across tasks (14, 29). A useful step is therefore to describe this structure by collecting data from a range of related assays within a single population of participants. Data-driven techniques such as clustering, latent class analysis or theory-driven techniques such as broader generative modelling approaches can be used to determine the latent structure of the assays. Identified latent structures can be fed back to step 1 to inform the further development of the assays, with the best performing (in terms of the metrics described in Table 1) being further deployed as described below.

Deployment: Establishing the potential of assays as predictors, targets and mediators

Next, the potential clinical utility of assays can be tested in proof-of-concept studies examining the predictive ability of the assay and/or the causal relationship between the process measured by the assay and clinically important outcomes such as symptoms.

Step 3a: Clinical prediction and covariation

Longitudinal observational studies may be used to assess whether an assay covaries with mental state changes or traits of interest and whether it has predictive validity, for example by predicting response to treatment (12). The ability of cohort studies to map the development of psychiatric symptoms may be enhanced by innovative study designs such as longitudinal yet brief “natural challenge” studies (30) which make use of patient and healthy cohorts likely to encounter precipitative events expected to result in a change in psychiatric status (for example, patients with an established mental illness starting a new treatment).

Prediction analyses will typically involve a combination of theory-driven and data-driven analysis, with data-driven analyses used to establish the most powerful predictors (12, 31) and to address issues of dimensionality reduction as described for latent structure validation above. Parameters derived from computational assays may be used as any other variable in data-driven analyses.

Step 3b: Causality and treatment targets

A second route by which computational assays may impact clinical practice is if the process measured by the assay constitutes a viable treatment target. That is, treatments may be developed specifically to alter the computationally defined process. This question hinges crucially on the causal relationship between the measured process and clinically relevant outcomes such as symptoms or functioning. Causality is most efficiently addressed using experimental medicine designs which manipulate the underlying, computationally measured, process and then assess the consequences of the manipulation on intermediate or clinical outcomes (where this is not possible, quasi-experimental designs may also be useful (32)). Potential manipulations may be selected from one or more pharmacological, brain stimulation, cognitive or psychotherapeutic technique, the key issue being the ability of the intervention to engage with and alter the computationally measured process.

Step 4: Clinical efficacy

Regardless of whether the goal of using a computational assay is to predict a clinically relevant outcome or to guide the development of a novel treatment, the efficacy of computationally informed approaches must ultimately be assessed in clinical trials. Such trials may, for example, randomly assign patients to be treated according to a predictive algorithm or standard treatment, or to receive a computationally informed intervention vs. a control.

In summary, these four steps describe a general pipeline of clinical computational assay optimization designed to yield reliable and valid assays that can be deployed in clinically informative study designs.

Evolution of the research environment

Computational assays can be applied to pre-existing datasets (33–35), and the sharing of relevant datasets and analytic procedures is clearly of great importance. However, going forward, the process of computational assay development and deployment outlined above requires substantial structural resources well beyond those of individual laboratories. At the very least, this includes shared core infrastructure, particularly in the domain of information technology. It will necessitate common data structures, which include meta-data relevant to measures, models and populations, and common ascertainment procedures across sites that enable individual labs to collect high-quality behavioral and clinical data and, where relevant, physiological or biological data from both public and clinical settings in a universal format (36). Curation of the data will be required to ensure that it is findable, accessible, interoperable and reusable from the outset. Due to rising concerns about data security on the one hand and the need to provide scientists access to data on the other, the secure storage and aggregation of data across sites using a platform which itself may support data analysis, is likely to be essential (37).

Finally, the complexity of the human mind, the diversity of processes of clinical relevance as well as the range of computational theories and interventions also represent a formidable intellectual challenge. It calls for a pooling of multiple strands of expertise and perspectives which can be achieved in appropriately designed multidisciplinary consortia distributed across laboratories that have a *common goal* and *share data and expertise*. Although it is beyond the scope of this paper to specify the precise nature and scope of such consortia we suggest that

they are likely to benefit from the inclusion of, at least, expert clinicians, experimentalists and theoreticians.

Conclusion

If computational methods are to deliver real advances for patients, we must ensure our approaches are reliable, robust, and address clinically meaningful questions. In this opinion paper we outline processes to improve the measurement properties and deployment of computational assays and highlight the importance of interdisciplinary collaboration.

Acknowledgements

The Banbury Centre Meeting was funded by grants from the Society for Biological Psychiatry; The William K. Warren Foundation; and The Carney Institute for Brain Science at Brown University. We thank Prof John Krystal, Prof Bruce Cuthbert, Prof Anne Churchland and Dr Michele Ferrante for invaluable discussion and advice.

Disclosures

Dr Browning is supported by a Clinician Scientist Fellowship from the MRC (MR/N008103/1) and by the NIHR Oxford Health Biomedical Research Centre. He has received travel expenses from Lundbeck for attending conferences and acted as a consultant for Jansen Research and CHDR. Dr Chatham is a full-time employee of Hoffman La Roche. Dr Baker has received consulting fees from Pear Therapeutics, BlackThorn Therapeutics, Niraxx Therapeutics, and AbleTo, Inc. Dr Chekroud holds equity in Spring Care Inc, Fitbit Inc, and UnitedHealthcare Inc; is lead inventor on three patent submissions relating to treatment for major depressive disorder [a) USPTO docket number Y0087.70116US00, b) USPTO. Provisional Appl. No. 62/491,660, and c) USPTO. Provisional Appl. No. 62/629,041]; and has consulted for Fortress Biotech on antidepressant drug development. Prof. Dayan is funded by the Max Planck Society. Prof Gold receives royalty payments from the Brief Assessment of Cognition in Schizophrenia. Prof Goldstein is supported by grants from the NIH: 1R01DA041528, 1R01DA047851, 1R01AT010627 and an SBIR-like Phase I NIDA subcontract to Soterix Medical 271201800035C. Dr Mourao-Miranda is supported by the Wellcome Trust under grant number WT102845/Z/13/Z. Over the past three years, Prof Phillips received an honorarium from Sunovion Pharmaceuticals. Over the past 3 years, Prof Pizzagalli has received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Compass, Posit

Science, and Takeda Pharmaceuticals and an honorarium from Alkermes for activities unrelated to the current review. Dr Powers receives support in the form of a K23 Career Development Award from the National Institute of Mental Health (K23 MH115252-01A1), a Career Award for Medical Scientists from the Burroughs-Wellcome Fund, and by the Yale University School of Medicine and Department of Psychiatry. Prof Roiser has acted as a consultant for Cambridge Cognition, Takeda, and GE Healthcare. Prof Stephan is funded by the René and Susanne Braginsky Foundation. Prof Frank is a consultant for Hoffman La Roche. Prof Paulus is an advisor to Spring Care, Inc., a behavioral health startup, he has received royalties for an article about methamphetamine in Uptodate and he has received support from the National Institute of General Medical Sciences (P20GM121312, Paulus). HDO has acted as a consultant for Lundbeck pharmaceuticals. Prof Carter, Dr Den Ouden, Dr Gillan, Prof Cools, Dr Hartley, Prof Kepecs, Dr Lawson, Prof Rindskopf, Dr Schmack, Prof Schiller, Dr Sebold and Dr Huys reported no biomedical financial interests or potential conflicts of interest.

References:

1. Huys QJM, Maia TV, Paulus MP (2016): Computational Psychiatry: From Mechanistic Insights to the Development of New Treatments. *BPS: CNNI*. 1: 382–385.
2. Montague PR, Dolan RJ, Friston KJ, Dayan P (2012): Computational psychiatry. *Trends Cogn Sci*. 16: 72–80.
3. Paulus MP, Huys QJM, Maia TV (2016): A Roadmap for the Development of Applied Computational Psychiatry. *BPS: CNNI*. 1: 386–392.
4. Stephan KE, Binder EB, Breakspear M, Dayan P, Johnstone EC, Meyer-Lindenberg A, *et al.* (2016): Charting the landscape of priority problems in psychiatry, part 2: pathogenesis and aetiology. *Lancet Psychiatry*. 3: 84–90.
5. Wang X-J, Krystal JH (2014): Computational psychiatry. *Neuron*. 84: 638–654.

6. Kishida KT, King-Casas B, Montague PR (2010): Neuroeconomic approaches to mental disorders. *Neuron*. 67: 543–554.
7. Browning M, Behrens TE, Jocham G, O'Reilly JX, Bishop SJ (2015): Anxious individuals have difficulty learning the causal statistics of aversive environments. *Nat Neurosci*. 18: 590–596.
8. Collins AGE, Albrecht MA, Waltz JA, Gold JM, Frank MJ (2017): Interactions Among Working Memory, Reinforcement Learning, and Effort in Value-Based Choice: A New Paradigm and Selective Deficits in Schizophrenia. *Biol Psychiatry*. 82: 431–439.
9. Huys QJM, Pizzagalli DA, Bogdan R, Dayan P (2013): Mapping anhedonia onto reinforcement learning: a behavioural meta-analysis. *Biol Mood Anxiety Disord*. 3: 12.
10. Powers AR, Mathys C, Corlett PR (2017): Pavlovian conditioning-induced hallucinations result from overweighting of perceptual priors. *Science*. 357: 596–600.
11. Lawson RP, Mathys C, Rees G (2017): Adults with autism overestimate the volatility of the sensory environment. *Nat Neurosci*. 20: 1293–1299.
12. Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH, *et al.* (2016): Cross-trial prediction of treatment outcome in depression: a machine learning approach. *Lancet Psychiatry*. 3: 243–250.
13. Harlé KM, Stewart JL, Zhang S, Tapert SF, Yu AJ, Paulus MP (2015): Bayesian neural adjustment of inhibitory control predicts emergence of problem stimulant use. *Brain*. 138: 3413–3426.
14. Wiecki TV, Poland J, Frank MJ (n.d.): Model-based cognitive neuroscience approaches to computational psychiatry clustering and classification. *Clinical Psychological Science: A Journal of the Association for Psychological Science*. 3: 378–399.
15. Huys QJM, Maia TV, Frank MJ (2016): Computational psychiatry as a bridge from neuroscience to clinical applications. *Nat Neurosci*. 19: 404–413.

16. Wiecki TV, Antoniades CA, Stevenson A, Kennard C, Borowsky B, Owen G, *et al.* (2016): A Computational Cognitive Biomarker for Early-Stage Huntington's Disease. *PLoS ONE*. 11: e0148409.
17. Brodersen KH, Schofield TM, Leff AP, Ong CS, Lomakina EI, Buhmann JM, Stephan KE (2011): Generative embedding for model-based classification of fMRI data. *PLoS Comput Biol*. 7: e1002079.
18. Behrens TEJ, Woolrich MW, Walton ME, Rushworth MFS (2007): Learning the value of information in an uncertain world. *Nat Neurosci*. 10: 1214–1221.
19. Pulcu E, Browning M (2017): Affective bias as a rational response to the statistics of rewards and punishments. *Elife*. 6. doi: 10.7554/eLife.27879.
20. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, *et al.* (2010): Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. *Am J Psychiatry*. 167: 748–751.
21. Hedge C, Powell G, Bompas A, Vivian-Griffiths S, Sumner P (2018): Low and variable correlation between reaction time costs and accuracy costs explained by accumulation models: Meta-analysis and simulations. *Psychol Bull*. 144: 1200–1227.
22. Price RB, Brown V, Siegle GJ (2019): Computational Modeling Applied to the Dot-Probe Task Yields Improved Reliability and Mechanistic Insights. *Biol Psychiatry*. 85: 606–612.
23. Kessels RPC (2019): Improving precision in neuropsychological assessment: Bridging the gap between classic paper-and-pencil tests and paradigms from cognitive neuroscience. *Clin Neuropsychol*. 33: 357–368.
24. Moutoussis M, Bullmore ET, Goodyer IM, Fonagy P, Jones PB, Dolan RJ, *et al.* (2018): Change, stability, and instability in the Pavlovian guidance of behaviour from adolescence to young adulthood. *PLoS Comput Biol*. 14: e1006679.
25. Shahar N, Hauser TU, Moutoussis M, Moran R, Keramati M, NSPN consortium, Dolan RJ (2019): Improving the reliability of model-based decision-making estimates in the two-

- stage decision task with reaction-times and drift-diffusion modeling. *PLoS Comput Biol.* 15: e1006803.
26. Hedge C, Powell G, Sumner P (2018): The reliability paradox: Why robust cognitive tasks do not produce reliable individual differences. *Behav Res Methods.* 50: 1166–1186.
 27. Enkavi AZ, Eisenberg IW, Bissett PG, Mazza GL, MacKinnon DP, Marsch LA, Poldrack RA (2019): Large-scale analysis of test-retest reliabilities of self-regulation measures. *Proc Natl Acad Sci USA.* 116: 5472–5477.
 28. Gillan CM, Daw ND (2016): Taking Psychiatry Research Online. *Neuron.* 91: 19–23.
 29. Poldrack RA, Yarkoni T (2016): From Brain Maps to Cognitive Ontologies: Informatics and the Search for Mental Structure. *Annu Rev Psychol.* 67: 587–612.
 30. Clarke P, MacLeod CM, Shirazee N (2008): Prepared for the worst: Readiness to acquire threat bias and susceptibility to elevate trait anxiety. *Emotion.* 8: 47–57.
 31. Calhoun VD, Lawrie SM, Mourao-Miranda J, Stephan KE (2017): Prediction of Individual Differences from Neuroimaging Data. *Neuroimage.* 145: 135–136.
 32. Marinescu IE, Lawlor PN, Kording KP (2018): Quasi-experimental causality in neuroscience and behavioural research. *Nat Hum Behav.* 2: 891–898.
 33. Etkin A, Patenaude B, Song YJC, Usherwood T, Rekshan W, Schatzberg AF, *et al.* (2015): A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. *Neuropsychopharmacology.* 40: 1332–1342.
 34. Trivedi MH, McGrath PJ, Fava M, Parsey RV, Kurian BT, Phillips ML, *et al.* (2016): Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. *J Psychiatr Res.* 78: 11–23.
 35. Auchter AM, Hernandez Mejia M, Heyser CJ, Shilling PD, Jernigan TL, Brown SA, *et al.* (2018): A description of the ABCD organizational structure and communication framework. *Dev Cogn Neurosci.* 32: 8–15.

36. Gorgolewski KJ, Alfaro-Almagro F, Auer T, Bellec P, Capotă M, Chakravarty MM, *et al.* (2017): BIDS apps: Improving ease of use, accessibility, and reproducibility of neuroimaging data analysis methods. *PLoS Comput Biol.* 13: e1005209.
37. Smucny J, Barch DM, Gold JM, Strauss ME, MacDonald AW, Boudewyn MA, *et al.* (2019): Cross-diagnostic analysis of cognitive control in mental illness: Insights from the CNTRACS consortium. *Schizophr Res.* . doi: 10.1016/j.schres.2019.01.018.
38. Wilson RC, Collins A (2019): *Ten simple rules for the computational modeling of behavioral data.* preprint, PsyArXiv. doi: 10.31234/osf.io/46mbn.

Table 1: Key Metrics of Reliability and Validity Relevant to Computational Measures (see also 38 for a summary)

| Specific Computational Measures of Reliability | |
|---|---|
| Parameter recovery, identifiability and sensitive range | <p>Parameter recovery is a process of validating parameterized generative models of behavior and/or neural data. It is performed <i>in silico</i>. A range of different parameter values are selected. These parameters are then used in the generative model to create synthetic data (at a realistic level of observation noise) which is passed back into the parameter estimation process; finally the recovered parameters are compared with the originals. The absolute difference between recovered and original parameters provides a measure of the ability of a task to estimate model parameters (if we can assume participant data can be described using a specific model), with smaller values being preferred. Parameter identifiability is a similar metric describing the degree to which model parameters exert distinct effects on the data and thus the degree to which differences in data can be confidently attributed to specific parameters. Parameter recovery and identifiability will generally not be constant over all parameter values (e.g. a very low inverse temperature will produce random behaviour to the detriment of recovery/identifiability of the <i>other</i> parameters of the model) and thus it is often useful to define the sensitive range of the parameters—the range of values over which parameter recovery and identifiability are achievable.</p> |
| Model recovery | <p>Model recovery assesses the degree to which a particular task can discriminate between different classes of generative models. This is achieved <i>in silico</i> by generating synthetic data using different models and then testing whether the process of model selection (see below) identifies the correct generative model. As for parameter recovery/identifiability, this can depend sensitively on the ranges of parameters used to generate the synthetic data.</p> |

| | |
|-----------------------------------|---|
| Model selection | <p>Where more than one model may be used to describe subject data, a process of model selection is used to select the “best” model. This process typically assesses the balance between the “fit” of the model (the degree to which the model can explain the data) and model complexity (i.e. its representational richness or flexibility to fit data in general). If two models explain the data similarly well, the simpler is preferred (Occam’s razor). Taking into account the fit/complexity trade-off is important since models with higher complexity (e.g. with more parameters) will have higher accuracy than simpler models but may be capturing measurement-specific noise (“overfitting”). Model selection may also concern the qualitative ability of the model to recapitulate some important features of the data. While many computational studies select a single, best model for all participants and compare model parameters between participants, it is also possible to assess whether participants differ in the model which best describes their data. The finding that data from different participants are best described by different models may in itself be interesting and may be described using an hierarchical model in which a higher level selects between separate lower level models (note that, in the absence of a single model used across all participants, between subject comparison of model parameters is not straightforward).</p> |
| Common Measures of Reliability | |
| Test-retest | <p>The degree to which the measures of individuals within a group maintain a consistent relationship across time is assessed by test-retest reliability. Test-retest performance is a critical metric for tasks which are required to measure stable, trait-like, within-subject, processes, and for studies using correlational or longitudinal designs.</p> |
| Split-half/interrater reliability | <p>Other forms of reliability such as split half reliability or interrater reliability estimate measurement variability and may be useful in certain computational tasks.</p> |

| | |
|--|--|
| Common Measures of Validity | |
| Clinical validity | Evidence for the clinical validity of a measure is provided by associations between it and clinically important outcomes such as symptom scores, treatment response or illness course. |
| Convergent/divergent validity | The degree to which a measure of a construct correlates with other measures of the same construct (convergent validity) and differs from measures of other constructs (divergent validity). These metrics therefore provide an assessment of how certain we can be that we are measuring an underlying construct (convergent validity) and the degree to which our measure provides the same/different information to alternative measures (divergent validity). Questions of convergent and divergent validity have largely been overlooked in computational psychiatry. As a result, it is not clear, for example, whether learning rates for positive outcomes in the plethora of available reward learning tasks measure the same thing. |
| Face and ecological validity | This reflects the degree to which a measurement appears to subjectively measure a process (face validity) and the degree to which it captures real life processes (ecological validity). Computational approaches are able to decompose the components of complex processes and may therefore facilitate the development of more ecologically valid measures of complex real-life interactions. |
| Practical Characteristics of the Measure | |
| Measure duration, complexity and cost | These summarise key practical costs of a measure which are essential when considering how it may be optimised for a particular study or population. |
| Translational Relevance of the Measure | |

| | |
|---|---|
| Cross species translational potential of the task | Depending on the specific question being addressed, the potential for a behavioral measure to be deployed in non-human species may be relevant for measurement selection. For example, validation of the ability of a computational assay to infer physiological mechanisms may require a degree of experimental control that cannot be achieved in humans. |
|---|---|

Figure 1: A suggested Process by which Computational Measures may be Optimized for Deployment in Clinical Studies

